81% rise in Victoza sales drives Novo Nordisk earnings

Article Date: 27/04/2012 10:33
81% rise in Victoza sales drives Novo Nordisk earnings

Vacancy Search

Quick job search

Advanced Search

Latest News

FDA okays Shire ADHD drug Vyvanse for binge eating

FDA okays Shire ADHD drug Vyvanse for binge eating

PM Society Award winners celebrate success

PM Society Award winners celebrate success

Losses at AbbVie but Humira sales soar again

Losses at AbbVie but Humira sales soar again

MS drug Tecfidera drives strong growth at Biogen

MS drug Tecfidera drives strong growth at Biogen

Upcoming events: Data from Xoma’s gevokizumab and Teva’s migraine antibody

Welcome to your weekly digest of approaching regulatory and clinical readouts. Data from Xoma’s gevokizumab in uveitis caused by Behçet’s syndrome are overdue, and are expected in the coming...

Venaxis at low risk of share price return with FDA rejection

Seeking US approval for a test that rules out appendicitis in emergency room patients with abdominal pain, Venaxis has found itself ruled out by the FDA.

'Outstanding' 2014 for Celgene as myeloma drugs soar

'Outstanding' 2014 for Celgene as myeloma drugs soar

Gov't invests £13.7m into stratified med projects

Gov't invests £13.7m into stratified med projects

Patients with rare CF being denied Vertex' Kalydeco

Patients with rare CF being denied Vertex' Kalydeco

Fourth FDA approval for blood cancer drug Imbruvica

Fourth FDA approval for blood cancer drug Imbruvica
more news